Comparison Centre
Two compounds, the same questions, no cherry-picking
Marketing compares compounds on whichever axis flatters them. This compares them on the same structured fields every time — including the awkward ones like human safety data and cancer-related mechanistic concerns.
BPC-157
The internet's favourite healing peptide: a mountain of rodent data and almost no controlled human evidence.
TB-500 / Thymosin beta-4
A genuine biological protein with real research history, and a separate online product that is not quite the same thing.
Clinical maturity
BPC-157
Preclinical, with very limited early human study activityTB-500 / Thymosin beta-4
Preclinical for musculoskeletal claims; limited clinical study in narrow indicationsHuman efficacy evidence
BPC-157
TB-500 / Thymosin beta-4
Preclinical evidence
BPC-157
TB-500 / Thymosin beta-4
Human safety evidence
BPC-157
TB-500 / Thymosin beta-4
Regulatory status
BPC-157
Not an approved medicine in any major region. The FDA has placed BPC-157 on the 503A Category 2 list of bulk substances that raise significant safety risks for compounding, which restricts its use in compounded preparations. It remains widely sold as a 'research chemical'.TB-500 / Thymosin beta-4
Not an approved medicine for injury recovery. Thymosin beta-4 has been studied clinically in specific ophthalmic and wound contexts; 'TB-500' as sold online is typically a synthetic fragment marketed outside medical supply. The FDA's 503A Category 2 list flags thymosin beta-4 fragments as a compounding safety concern. It is also prohibited in sport.Common claims
BPC-157
- · Heals tendons, ligaments and muscle tears
- · Repairs the gut lining and helps IBD
- · Reduces inflammation and speeds recovery from almost anything
TB-500 / Thymosin beta-4
- · Accelerates soft-tissue and tendon healing
- · Reduces scar tissue
- · Improves flexibility and recovery in athletes
Confidence in those claims
BPC-157
TB-500 / Thymosin beta-4
Cancer-related mechanistic considerations
BPC-157
The most common concern is that promoting angiogenesis could theoretically support tumour growth. This is a mechanistic hypothesis (Level 1), not a demonstrated human cancer risk — no human data show BPC-157 causes cancer. Equally, no human data show it is safe in people with cancer. Both statements are true at once, and that is exactly the point.TB-500 / Thymosin beta-4
Thymosin beta-4 promotes angiogenesis and cell migration, and elevated expression has been described in some tumour contexts. That is a mechanistic and observational concern worth naming honestly; it is not proof that administering it causes cancer in humans. There is no human evidence either way.Bottom-line interpretation
BPC-157
Interesting preclinical science. Treating it as an established human treatment is not supported.TB-500 / Thymosin beta-4
Interesting preclinical science. Treating it as an established human treatment is not supported.A comparison is not a recommendation